Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Ovarian Neoplasms 5Neoplasms 5Neoplasm Metastasis 5Fallopian Tube Neoplasms 4Carcinoma 4Carcinoma, Renal Cell 3Sarcoma 2Glioblastoma 2Gastrointestinal Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Brain Neoplasms 2Stomach Neoplasms 1Sarcoma, Endometrial Stromal 1Renal Insufficiency 1Rectal Neoplasms 1Prostatic Neoplasms 1Oligodendroglioma 1Melanoma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Kidney Neoplasms 1Kidney Diseases 1Hemangiosarcoma 1Gliosarcoma 1Glioma 1Congenital Abnormalities 1

Interventions

Cytarabine 60Etoposide 24Daunorubicin 24Filgrastim 19Idarubicin 16Mitoxantrone 13Busulfan 12tipifarnib 11Gemtuzumab 10fludarabine phosphate 9Peripheral Blood Stem Cell Transplantation 9Cyclophosphamide 9Flow Cytometry 8Clofarabine 8Azacitidine 8sargramostim 7Methotrexate 7Gene Expression Profiling 7Topotecan 6Cyclosporine 6valspodar 5alvocidib 5Radiotherapy 5Granulocyte Colony-Stimulating Factor 5aldesleukin 4Observation 4Bortezomib 4Arsenic Trioxide 4Antilymphocyte Serum 4Whole-Body Irradiation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Myelomonocytic, Acute × trebananib × Clear all
NCT01555268 2022-09-13

Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia

Roswell Park Cancer Institute

Phase 1 Completed
24 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡